The findings revealed a potential mechanism of TKI resistance via the NAT10-ac4C-FATP4-CPT1A axis and indicated that targeting NAT10 with Remodelin may effectively address clinical EGFR-TKI resistance in NSCLC. This evidence concerns the gene SLC27A4 and non-small cell lung carcinoma.